ClinicalTrials.gg
CompletedNCT01769378AWARD-8Updated Jan 25, 2016Results posted

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

A Phase 3 interventional study of Placebo and Dulaglutide in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 31 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
21st of 54
300 · median 159
Started
2013
the only one that year
Phase 3
22 of 54
1 open now
Registered
28th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is the only one that started in 2013, is one of 22 in phase 3, and was the 28th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Stable dose of sulfonylurea that is at least 50% of the maximum approved dose per the local label for at least 3 months prior to the first study visit
  • Have an value of ≥7.5% and ≤9.5%, as determined by the central laboratory draw performed at the first study visit
  • Accept continued treatment with sulfonylurea therapy, throughout the trial, as required per protocol
  • Men and nonpregnant women aged ≥18 years
  • Stable weight (±5%) ≥3 months prior to screening
  • (BMI) ≤45 kilograms per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have been treated with ANY other antihyperglycemic medications (other than sulfonylurea) at the time of the first study visit or within 3 months prior to the first study visit
  • Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks; any insulin within 3 months prior to the first study visit is exclusionary
  • Have been treated with drugs that promote weight loss within 3 months prior to the first study visit
  • Are receiving chronic (>14 days) systemic therapy or have received such therapy within the 4 weeks immediately prior to the first study visit
  • Have had any of the following Cardiovascular (CV) conditions within 2 months prior to the first study visit: acute myocardial infarction, Class III or Class IV heart failure, or cerebrovascular accident
  • Have a known gastric emptying abnormality (eg, severe diabetic gastroparesis or gastric outlet obstruction) or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or level >2.5 times the
  • Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis within the 3 month period prior to the first study visit
  • Have an estimated [eGFR] \<30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2), calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation as determined by the central laboratory at the first study visit
  • Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia (this exclusion includes those participants with a family history of MEN 2A or 2B, whose family history for the syndrome is Rearranged during Transfection (RET) negative; the only exception for this exclusion will be for participants whose family members with MEN 2A or 2B have a known RET mutation and the potential participant for the study is negative for that RET mutation)
  • Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma (including sporadic, familial or part of MEN 2A or 2B syndrome)
  • Have a serum calcitonin ≥20 picogram per milliliter (pg/mL) as determined by the central laboratory at the first study visit
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.

    Drug: Placebo · Drug: Glimepiride

  • Experimental
    Dulaglutide

    Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.

    Drug: Dulaglutide · Drug: Glimepiride

Interventions

  • DrugPlacebo

    Administered SQ

  • Administered SQ

    Also known as: LY2189265

  • Administered PO

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks

    Least Squares Means (LS Means) of the HbA1c change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline HbA1c as covariate, via a Mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).

    Time frame: Baseline, 24 Weeks

Secondary outcomes

  1. Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks

    The percentage of participants who achieved the target HbA1c values at endpoint will be analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes country, treatment, visit and treatment interaction and baseline HbA1c as a continuous covariate.

    Time frame: 24 Weeks

  2. Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks

    LS Means of the FSG from baseline to primary endpoint was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FSG as covariate, via Analysis of Covariance Model (ANCOVA) with Last Observation Carried Forward (LOCF).

    Time frame: Baseline, 24 Weeks

  3. Change From Baseline in Body Weight at 24 Weeks

    LS Means of the body weight change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline body weight as covariate, via a MMRM analysis using REML.

    Time frame: Baseline, 24 Weeks

  4. Change From Baseline in Body Mass Index (BMI) at 24 Weeks

    LS Means of the BMI change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline BMI as covariate, via a MMRM analysis using REML.

    Time frame: Baseline, 24 Weeks

  5. Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks

    LS Means of the SMPG change from baseline to primary endpoint at week 24 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG value as covariate, via a MMRM analysis using REML.

    Time frame: Baseline, 24 Weeks

  6. Number of Participants With Reported and Adjudicated Cardiovascular Events

    Information on cardiovascular (CV) risk factors was collected at baseline. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

    Time frame: Baseline through 24 Weeks, 30-day Follow Up

  7. Number of Participants With Adjudicated Acute Pancreatitis Events

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 24 Weeks, 30-day Follow Up

  8. Change From Baseline in Calcitonin at 24 Weeks

    Time frame: Baseline, 24 Weeks

  9. Percentage of Participants With Self-Reported Events of Hypoglycemia

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). Percentage is calculated as the number of participants reporting HE each visit/ the total number of participants reporting HE during the entire study treatment period.

    Time frame: Baseline through 24 Weeks

  10. Rate of HE Adjusted Per 30 Days

    The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.

    Time frame: Baseline through 24 weeks

  11. Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia

    Additional Intervention: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.

    Time frame: Baseline through 24 Weeks

  12. Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia

    An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.

    Time frame: Baseline through 24 Weeks

  13. Dulaglutide Anti-Drug Antibodies (ADA)

    Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant is considered to have TE dulaglutide ADA if the participant has at least one titer that is treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline up to 4 Weeks Post-Last Dose of Study Drug

  14. Change From Baseline in Lipase

    A summary of changes in lipase evaluation from baseline to endpoint.

    Time frame: Baseline, 24 Weeks

  15. Change From Baseline in Amylase

    A summary of changes in amylase evaluation from baseline to endpoint.

    Time frame: Baseline, 24 Weeks

07

Results

Posted Oct 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneDulaglutidePlacebo
Started24060
Received at least 1 dose of study drug23960
Completed21556
Not completed254
Withdrew: Adverse event100
Withdrew: Entry criteria not met10
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject103
Withdrew: Sponsor decision10
Withdrew: Lost to follow-up20

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks

Least Squares Means (LS Means) of the HbA1c change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline HbA1c as covariate, via a Mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · percent change of HbA1c
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks
percent change of HbA1cDulaglutidePlacebo
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks-1.38 ± 0.08-0.11 ± 0.14
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls squares mean difference: -1.27 · 95% CI -1.57 to -0.97
SecondaryPercentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks

The percentage of participants who achieved the target HbA1c values at endpoint will be analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes country, treatment, visit and treatment interaction and baseline HbA1c as a continuous covariate.

Time frame:
24 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks
percentage of participantsDulaglutidePlacebo
Percent Achieved <7.0 HbA1c Level55.318.9
Percent Achieved ≤6.5 HbA1c Level40.09.4
Statistical analysis
  • Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.37 · 95% CI 3.82 to 33.84Sequential gatekeeping strategy was used to adjust for multiplicity.
  • Dulaglutide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.45 · 95% CI 3.71 to 35.34
SecondaryChange From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks

LS Means of the FSG from baseline to primary endpoint was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FSG as covariate, via Analysis of Covariance Model (ANCOVA) with Last Observation Carried Forward (LOCF).

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks
milligrams per deciliter (mg/dL)DulaglutidePlacebo
Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks-30.60 ± 4.462.93 ± 6.76
Statistical analysis
  • Dulaglutide vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -33.54 · 95% CI -46.55 to -20.53Sequential gatekeeping strategy was used to adjust for multiplicity.
SecondaryChange From Baseline in Body Weight at 24 Weeks

LS Means of the body weight change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline body weight as covariate, via a MMRM analysis using REML.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight at 24 Weeks
kilograms (kg)DulaglutidePlacebo
Change From Baseline in Body Weight at 24 Weeks-0.91 ± 0.21-0.24 ± 0.40
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.120 · Least squares mean difference: -0.68 · 95% CI -1.53 to 0.18Sequential gatekeeping strategy was used to adjust for multiplicity.
SecondaryChange From Baseline in Body Mass Index (BMI) at 24 Weeks

LS Means of the BMI change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline BMI as covariate, via a MMRM analysis using REML.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · kilograms per/square meter kg/m^2
Change From Baseline in Body Mass Index (BMI) at 24 Weeks
kilograms per/square meter kg/m^2DulaglutidePlacebo
Change From Baseline in Body Mass Index (BMI) at 24 Weeks-0.32 ± 0.08-0.10 ± 0.15
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.161 (No adjustment for multiplicity) · Least squares mean difference: -0.23 · 95% CI -0.54 to 0.09
SecondaryChange From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks

LS Means of the SMPG change from baseline to primary endpoint at week 24 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG value as covariate, via a MMRM analysis using REML.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks
mg/dLDulaglutidePlacebo
Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks-37.22 ± 3.10-8.27 ± 4.77
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -28.95 · 95% CI -38.49 to -19.40
SecondaryNumber of Participants With Reported and Adjudicated Cardiovascular Events

Information on cardiovascular (CV) risk factors was collected at baseline. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

Time frame:
Baseline through 24 Weeks, 30-day Follow Up
Reported as:
Number · participants
Number of Participants With Reported and Adjudicated Cardiovascular Events
participantsDulaglutidePlacebo
Any reported CV events20
Any adjudicated nonfatal CV events20
Any confirmed adjudicated CV deaths00
SecondaryNumber of Participants With Adjudicated Acute Pancreatitis Events

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 24 Weeks, 30-day Follow Up
Reported as:
Number · participants
Number of Participants With Adjudicated Acute Pancreatitis Events
participantsDulaglutidePlacebo
Number of Participants With Adjudicated Acute Pancreatitis Events00
SecondaryChange From Baseline in Calcitonin at 24 Weeks
Time frame:
Baseline, 24 Weeks
Reported as:
Median · picogram per milliliter (pg/ml)
Change From Baseline in Calcitonin at 24 Weeks
picogram per milliliter (pg/ml)DulaglutidePlacebo
Change From Baseline in Calcitonin at 24 Weeks0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryPercentage of Participants With Self-Reported Events of Hypoglycemia

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). Percentage is calculated as the number of participants reporting HE each visit/ the total number of participants reporting HE during the entire study treatment period.

Time frame:
Baseline through 24 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Events of Hypoglycemia
percentage of participantsDulaglutidePlacebo
Symptomatic11.31.7
Asymptomatic13.41.7
Probable2.50.0
Severe00
Nocturnal6.71.7
SecondaryRate of HE Adjusted Per 30 Days

The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.

Time frame:
Baseline through 24 weeks
Reported as:
Mean · number of events/participants/30 days
Rate of HE Adjusted Per 30 Days
number of events/participants/30 daysDulaglutidePlacebo
Total HE0.19 ± 0.590.01 ± 0.03
Documented symptomatic HE0.07 ± 0.330.00 ± 0.02
Asymptomatic HE0.11 ± 0.450.00 ± 0.02
Severe HE0 ± 0.00 ± 0.0
Nocturnal HE0.02 ± 0.160.00 ± 0.02
Probable symptomatic HE0.01 ± 0.040 ± 0.0
SecondaryPercentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia

Additional Intervention: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.

Time frame:
Baseline through 24 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia
percentage of participantsDulaglutidePlacebo
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia2.111.7
SecondaryTime to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia

An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.

Time frame:
Baseline through 24 Weeks
Reported as:
Mean · weeks
Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia
weeksDulaglutidePlacebo
Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia22.59 ± 0.3622.47 ± 0.66
SecondaryDulaglutide Anti-Drug Antibodies (ADA)

Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant is considered to have TE dulaglutide ADA if the participant has at least one titer that is treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline up to 4 Weeks Post-Last Dose of Study Drug
Reported as:
Number · participants
Dulaglutide Anti-Drug Antibodies (ADA)
participantsDulaglutide
Dulaglutide Anti-Drug Antibodies (ADA)2
SecondaryChange From Baseline in Lipase

A summary of changes in lipase evaluation from baseline to endpoint.

Time frame:
Baseline, 24 Weeks
Reported as:
Median · Units/Liter
Change From Baseline in Lipase
Units/LiterDulaglutidePlacebo
Change From Baseline in Lipase8.0 (1.0 to 18.0)4.5 (-2.5 to 15.5)
SecondaryChange From Baseline in Amylase

A summary of changes in amylase evaluation from baseline to endpoint.

Time frame:
Baseline, 24 Weeks
Reported as:
Median · Units/Liter
Change From Baseline in Amylase
Units/LiterDulaglutidePlacebo
Change From Baseline in Amylase8.0 (1.0 to 18.0)2.0 (-5.0 to 11.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dulaglutide—9/239 (3.8%)44/239 (18.4%)
Placebo—0/60 (0%)3/60 (5%)
Most frequent serious events
Most frequent serious events
EventDulaglutidePlacebo
Angina pectorisCardiac disorders1/2390/60
OsteomyelitisInfections and infestations1/2390/60
Otitis mediaInfections and infestations1/2390/60
Pulmonary tuberculosisInfections and infestations1/2390/60
Ulna fractureInjury, poisoning and procedural complications1/2390/60
HypoglycemiaMetabolism and nutrition disorders1/2390/60
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/2390/60
Anaplastic astrocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2390/60
Cerebrovascular accidentNervous system disorders1/2390/60
Most frequent other events
Most frequent other events
EventDulaglutidePlacebo
NauseaGastrointestinal disorders25/2390/60
DiarrhoeaGastrointestinal disorders20/2390/60
EructationGastrointestinal disorders14/2390/60
HyperglycemiaMetabolism and nutrition disorders1/2393/60

Baseline characteristics

Intent to treat (ITT) population: all randomized participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)DulaglutidePlaceboTotal
<=18 years000
Between 18 and 65 years18249231
>=65 years571168
Age, Continuous
Age, Continuous(years)DulaglutidePlaceboTotal
Mean57.73 ± 10.2058.23 ± 7.4057.83 ± 9.70
Sex: Female, Male
Sex: Female, Male(Participants)DulaglutidePlaceboTotal
Female13532167
Male10428132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DulaglutidePlaceboTotal
Hispanic or Latino11227139
Not Hispanic or Latino12733160
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DulaglutidePlaceboTotal
American Indian or Alaska Native21526
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American7411
White20247249
More than one race628
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)DulaglutidePlaceboTotal
Argentina29837
Austria415
Romania781896
United States571471
South Africa7310
Mexico401050
Slovenia13316
Croatia9211
Puerto Rico213
08

Study locations

31 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chino, California 91710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33175, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trenton, New Jersey 08611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York 10461, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beaver, Pennsylvania 15009, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, (C1056ABJ), Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, C1204AAD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corrientes, 3400, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5026, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zams, 6511, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krapinske Toplice, 49217, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osijek, 31000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rijeka, HR-51000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Slavonski Brod, 35000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Varazdin, 42000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, 10000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 06700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampico, 89000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alba-Iulia, 510053, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 13682, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800098, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iasi, 700547, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oradea, 410169, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sibiu, 550371, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Celje, 3000, Slovenia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ljubljana, 1000, Slovenia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloemfontein, 9301, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durban, 4092, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Somerset West, 7130, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2013
First posted
Jan 16, 2013
Start
Jan 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Oct 14, 2015
Last update
Jan 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01769378
Responsible party
Sponsor
First posted
Jan 16, 2013
Start date
Jan 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Oct 14, 2015
Last update
Jan 25, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion